- Home
- ANTX
as 11-05-2025 11:49am EST
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | MENLO PARK |
| Market Cap: | 34.4M | IPO Year: | 2022 |
| Target Price: | $2.00 | AVG Volume (30 days): | 66.7K |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.25 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.97 - $1.68 | Next Earning Date: | 11-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest AN2 Therapeutics Inc. News
ANTX Breaking Stock News: Dive into ANTX Ticker-Specific Updates for Smart Investing
Business Wire
5 months ago
AN2 Therapeutics Announces Poster Presentation Highlighting M. Abscessus Data at 2025 Colorado Mycobacteria Conference
Business Wire
6 months ago
AN2 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business and Scientific Highlights
Business Wire
6 months ago
AN2 Therapeutics Reports Data from the Phase 3 Portion of Previously Terminated EBO-301 Study and Outlines Future Milestones from Boron Chemistry Pipeline
Business Wire
6 months ago
AN2 Therapeutics to Participate in Citizens JMP Life Sciences Conference
Simply Wall St.
7 months ago
Here's Why We're Watching AN2 Therapeutics' (NASDAQ:ANTX) Cash Burn Situation
Business Wire
8 months ago
AN2 Therapeutics to Present at Leerink Partners Global Healthcare Conference
Simply Wall St.
8 months ago
Golden Sun Health Technology Group Leads 3 US Penny Stocks Worth Monitoring
Business Wire
8 months ago
AN2 Provides Strategic Update for Phase 3 EBO-301 Trial in Treatment Refractory MAC Lung Disease
Compare ANTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ANTX AN2 Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.